BC Extra | Sep 30, 2019
Clinical News

Stable disease signal pushes Amgen KRAS inhibitor forward in colorectal cancer

Despite a far lower partial response rate in colorectal cancer than in lung cancer, Amgen plans to expand its colorectal trials and gear up for combination studies of closely watched KRAS inhibitor AMG 510, citing...
BC Innovations | Jun 28, 2019
Product Development

How Array stayed alive long enough to grow up

Array’s 21-year journey as an independent platform company, culminating in an $11.4 billion buyout, required shifting focus from research to development and back again. The acquisition sends a message that developing focused expertise and sticking...
BC Extra | Jun 17, 2019
Company News

Array takeout buoys biotechs, strengthens Pfizer in targeted oncology

Public biotechs got a boost Monday on the strength of Pfizer's $11.4 billion buyout of Array, signaling that continued M&A interest in the sector can help reverse the loss in momentum that has led to...
BioCentury | May 10, 2019
Product Development

Exelixis to fuel pipeline growth with Cabometyx cash flows

On the back of the successful launch of Cabometyx cabozantinib, Exelixis is not only using the increased free cash flow to expand the drug’s label, it also thinks it has the firepower to build out...
BC Innovations | Nov 6, 2018
Distillery Techniques

Assays and screens; biomarkers

TECHNOLOGY: Cellular assays; gene profiling; tissue markers Gene profiling coupled with cell-based assays of patient samples could help predict drug responses in AML patients. In tumor samples from 363 patients, whole-exome sequencing plus genotyping of...
BC Innovations | Oct 11, 2018
Distillery Therapeutics

Cancer

INDICATION: Melanoma Cell culture and mouse studies suggest the generic antibiotic nifuroxazide could help treat melanoma. In two human metastatic melanoma cell lines, nifuroxazide plus the BRAF inhibitor Zelboraf vemurafenib and the MEK inhibitor Mekinist...
BC Extra | Oct 10, 2018
Politics & Policy

China adds insurance coverage for 17 cancer therapies

China's National Medical Insurance Administration added 17 cancer drugs to the National Reimbursement Drug List (NRDL) for coverage by the country's medical insurance program. The prices will go into effect by the end of October...
BC Innovations | Sep 28, 2018
Tools & Techniques

Deconstructing tox in immuno-oncology

The best route to improving preclinical toxicity in immunotherapies could lie in reverse translation, feeding clinical data back into the preclinical space to inform model development, rather than trying to guess a priori what the...
BC Innovations | Aug 23, 2018
Distillery Therapeutics

Endocrine/metabolic

INDICATION: Cushing disease Patient sample and cell culture studies suggest the BRAF V600E inhibitor Zelboraf vemurafenib could help treat Cushing disease, which involves excessive cortisol production triggered by ACTH-secreting pituitary adenomas. In 91 tumor samples...
BC Extra | Aug 17, 2018
Politics & Policy

China unveils cancer drugs for medical insurance access negotiation

China's State Medical Insurance Administration announced 18 cancer drugs that will be included in 2018 medical insurance access negotiations. Companies with drugs on the list will now enter into negotiations to include the drugs on...
Items per page:
1 - 10 of 286